The use of intramyocardial mesenchymal precursor cells (MPC) to promote cardiac recovery is fast losing favour with new evidence showing the cell therapy does not improve temporary weaning from left ventricular assist devices (LVAD). The multicentre US study comprised 159 patients with end-stage heart failure randomised to receive either an intramyocardial injection of MPCs or ...
Call to halt stem cell use in HF as another trial disappoints
By Mardi Chapman
4 Apr 2019